Current status of tolerance in kidney transplantation

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 6, 2016, Pages 591-601

  Chandran, Sindhu ^a   Feng, Sandy ^b  

^a Division of Nephrology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chimerism; kidney transplant; tolerance

Indexed keywords

B LYMPHOCYTE; CELL THERAPY; CHIMERA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MASSACHUSETTS; NONMYELOABLATIVE CONDITIONING; PATIENT SAFETY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; TRANSPLANTATION TOLERANCE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

B-LYMPHOCYTES; CHIMERISM; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84987870782     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000269     Document Type: Review

References (47)

1. Massart A, Pallier A, Pascual J, et al. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrol Dial Transplant 2016; 31:1002-1013.
2. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120:1836-1847.
3. Soulillou JP, Giral M, Brouard S. Operational tolerance in kidney transplantation- improved terminology may enable more precise investigation. Transplantation 2013; 96:e36-e38.
4. Louis S, Braudeau C,Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81:398-407.
5. Moraes-Vieira PM, Takenaka MC, Silva HM, et al. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol 2012; 142:117-126.
6. Baron D, Ramstein G, Chesneau M, et al. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int 2015; 87:984-995
7. Chesneau M, Pallier A, Braza F, et al. Unique B cell differentiation profile in tolerant kidney transplant patients. Am J Transplant 2014; 14:144-155.
8. Chesneau M, Michel L, Dugast E, et al. Tolerant kidney transplant patients produce B cells with regulatory properties. J Am Soc Nephrol 2015; 26:2588-2598.
9. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity (Edinb) 1951; 5:279-397.
10. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102:400-401.
11. Butcher JA, Hariharan S, Adams MB, et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: A report of six cases, with and without immunosuppression. Clin Transplant 1999; 13:330-335.
12. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014; 14:1599-1611.
13. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353- 361.
14. Leventhal JR, Mathew JM, Ildstad S, et al. HLA identical nonchimeric and HLA disparate chimeric renal transplant tolerance. Clin Transpl 2013; 27:145- 156.
15. Leventhal JR, Mathew JM, Salomon DR, et al. Nonchimeric HLA-identical renal transplant tolerance: Regulatory immunophenotypic/genomic biomarkers. Am J Transplant 2016; 16:221-234.
16. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73:1386-1391.
17. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12:1133-1145.
18. Scandling JD, Busque S, Shizuru JA, et al. Induced immune tolerance for kidney transplantation. N Engl J Med 2011; 365:1359-1360.
19. Scandling JD, Busque S, Shizuru JA, et al. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 2015; 15:695-704.
20. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:124ra28.
21. Kaufman CL, Colson YL, Wren SM, et al. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84:2436-2446.
22. Colson YL, Christopher K, Glickman J, et al. Absence of clinical GVHD and the in vivo induction of regulatory T cells after transplantation of facilitating cells. Blood 2004; 104:3829-3835.
23. Huang Y, Bozulic LD, Miller T, et al. CD8α + plasmacytoid precursor DCs induce specific regulatory T cells that enhance HSC engraftment in vivo. Blood 2011; 117:2494-2505.
24. Leventhal JR, Elliott MJ, Yolcu ES, et al. Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation 2015; 99:288-298.
25. Buhler LH,SpitzerTR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerismin patients with multiplemyeloma and end-stage renal disease. Transplantation 2002; 74:1405-1409.
26. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6:2121-2133.
27. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-484.
28. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91:672-676.
29. Kawai T, Sachs DH, Cosimi AB. Tolerance to vascularized organ allografts in large-animal models. Curr Opin Immunol 1999; 11:516-520.
30. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4:1391-1398.
31. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 2010; 90:1607-1615.
32. Andreola G, Chittenden M, Shaffer J, et al. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant 2011; 11:1236-1247.
33. Morris H, DeWolf S, Robins H, et al. Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med 2015; 7:272ra10
34. Leventhal JR, Mathew JM, Salomon DR, et al. Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol 2013; 24:1376-1385.
35. Cirocco RE, Carreno MR, Mathew JM, et al. FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation 2007; 83:1611-1619.
36. Mathew JM, Ciancio G, Burke GW, et al. Immune 'tolerance profiles' in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol 2010; 71:566-576.
37. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-368.
38. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013; 95:169-176.
39. Leventhal J, Galvin J, Stare D, et al. Seven year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients [abstract]. Am J Transplant 2016; 16 (Suppl 3):269-270.
40. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14:88-92.
41. Pilat N, Baranyi U, Klaus C, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant 2010; 10:751-762.
42. Pilat N, Klaus C, Hock K, et al. Polyclonal recipient nTregs are superior to donor or third-party Tregs in the induction of transplantation tolerance. J Immunol Res 2015; 2015:562935.
43. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
44. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-1150.
45. Guinan EC, Cole GA, Wylie WH, et al. Ex vivo costimulatory blockade to generate regulatory T cells from patients awaiting kidney transplantation. Am J Transplant 2016; 16:2187-2195.
46. Skaro A, LeFever A, Matthew J, et al. Results of a phase 1 trial of Treg adoptive cell transfer (TRACT) in de novo living donor kidney transplant recipients [abstract]. Am J Transplant 2016; 15 (Suppl 3):271.
47. Chandran S, Tang Q, Sarwal M, et al. Polyclonal Treg Adoptive Therapy for Control of Subclinical Kidney Transplant Inflammation (TASK Pilot Trial) [abstract]. Am J Transplant 2016; 16 (Suppl 3):348.